Evaluation of Droplet Digital PCR Rapid Detection Method and Precise Diagnosis and Treatment for Suspected Sepsis
- Disease/Condition
- Sepsis,Septic Shock
- Drug/Device/Intervention
- droplet digital PCR method
- Study type
- Interventional
- Intervention type
- diagnostic test
- Primary sponsor
- Huashan Hospital
- Location
- Hefei,Changsha,Nanjing,Wuxi,Shanghai,Shanghai,Shanghai,Rui'an,Wenzhou, China
- Phase
- N/A
- Start date
- Nov 29, 2021
- End date
- Jun 01, 2023
- Enrollment
- 2000 participants
Sensitivity,Specificity
Sepsis is a significant public health concern worldwide, with high morbidity and mortality.
 With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen
 detection is of crucial importance. Until now, culture-based detection methods represent the
 diagnostic gold standard, although they are characterized by numerous limitations.
 Culture-independent molecular diagnostic procedures may represent a promising alternative. In
 particular, droplet digital PCR (ddPCR) is a novel one-step PCR assay that achieves higher
 accuracy and sensitivity in detecting causing pathogens in patients with bloodstream
 infections.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05190861
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05190861 through Pure Global AI's free database. This phase not specified trial is sponsored by Huashan Hospital and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.